160 related articles for article (PubMed ID: 11474633)
21. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
Wilson R; Schentag JJ; Ball P; Mandell L;
Clin Ther; 2002 Apr; 24(4):639-52. PubMed ID: 12017408
[TBL] [Abstract][Full Text] [Related]
22. Safety of trovafloxacin in treatment of lower respiratory tract infections.
Williams D; Hopkins S
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):454-8. PubMed ID: 9758292
[TBL] [Abstract][Full Text] [Related]
23. Gemifloxacin: a new fluoroquinolone.
Blondeau JM; Missaghi B
Expert Opin Pharmacother; 2004 May; 5(5):1117-52. PubMed ID: 15155113
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
Pullman J; Champlin J; Vrooman PS
Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
[TBL] [Abstract][Full Text] [Related]
25. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
[TBL] [Abstract][Full Text] [Related]
26. Gemifloxacin: survival of the fittest.
Mandell L
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
28. Comment on: Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
Hammerschlag MR
J Antimicrob Chemother; 2007 Oct; 60(4):902-3; author reply 903. PubMed ID: 17681976
[No Abstract] [Full Text] [Related]
29. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
30. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
Moola S; Hagberg L; Churchyard GA; Dylewski JS; Sedani S; Staley H
Chest; 1999 Oct; 116(4):974-83. PubMed ID: 10531162
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection.
Berry V; Page R; Satterfield J; Singley C; Straub R; Woodnutt G
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():79-85. PubMed ID: 10824037
[TBL] [Abstract][Full Text] [Related]
32. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
[TBL] [Abstract][Full Text] [Related]
33. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
34. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
[TBL] [Abstract][Full Text] [Related]
35. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection.
Berry V; Page R; Satterfield J; Singley C; Straub R; Woodnutt G
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():87-93. PubMed ID: 10824038
[TBL] [Abstract][Full Text] [Related]
37. [Use of trovafloxacin therapy in community-acquired pneumonia].
Luna CM; Gené RJ
Medicina (B Aires); 1999; 59 Suppl 1():31-8. PubMed ID: 10436552
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
39. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
Blondeau JM; Tillotson G
Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics to combat resistance.
Woodnutt G
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
